Ablative Solutions News Today

/PRNewswire/ -- Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal...

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),

Welcome to the MassDevice Fast Five medtech news podcast. Here’s what you need to know for today, December 20, 2023.

Ablative Solutions announced today that its TARGET BP I pivotal trial evaluating its Peregrine System kit met its primary endpoint.

Judith Leblanc and co-workers report a cluster-randomized trial evaluating intensive screening for SARS-CoV-2 infection in emergency departments.

This clinical trial compares the efficacy of intubation withholding vs routine practice on clinical outcomes of comatose patients with acute poisoning and a Gla

Imaging catheters should be part of most coronary stent procedures and probably all complex cases, advocates say. Several new studies strengthen their case.

The two types of imaging catheter, as guides for coronary stent targeting and deployment, led to similar clinical outcomes in the OCTIVUS trial. A meta-analysis backed it up.

April 12, 2023—Ablative Solutions, Inc. announced the completion of patient enrollment in the TARGET BP I study, which is evaluating alcohol-med